Revenio Group Oyj
OTC:REVXF
Revenio Group Oyj
Revenio Group Oyj is a globally operating health technology, which engages in the detection of glaucoma, osteoporosis, skin cancer, and asthma. The company is headquartered in Vantaa, Etela-Suomen and currently employs 184 full-time employees. The company went IPO on 2003-01-01. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. The company distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.
Revenio Group Oyj is a globally operating health technology, which engages in the detection of glaucoma, osteoporosis, skin cancer, and asthma. The company is headquartered in Vantaa, Etela-Suomen and currently employs 184 full-time employees. The company went IPO on 2003-01-01. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. The company distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.
Strong Start: Revenio delivered a robust Q1 with net sales of EUR 26.1 million, up 10.5% year-on-year, and record profitability.
Broad-Based Growth: Sales grew in all regions, notably strong in China and India, with key products like tonometers and imaging devices performing well.
Margin Performance: EBIT reached EUR 6.6 million, representing 25.4% of revenue, and gross margin improved slightly due to accounting changes.
Tariff Impact Managed: Management estimates a EUR 0.8–1.4 million earnings impact from U.S. tariffs in Q2–Q4 if unmitigated, but plans price increases to offset this.
Product Launches: The new MAIA and TONOVET Pro devices are seeing positive early demand; microperimeter product was launched after FDA and CE approvals.
Guidance Maintained: Full-year guidance for 6–15% FX-adjusted net sales growth and good profitability remains unchanged.
Cost Increases: Higher personnel and marketing costs contributed to a 10% rise in fixed costs, partly due to headcount growth and salary hikes.
